| Chemical Name |
(20S)-Protopanaxatriol |
| CAS Number |
34080-08-5 |
| MDL Number |
MFCD11041271 |
| Molecular Formula |
C30H52O4 |
| Molecular Weight |
476.73 |
| Synonyms |
20(S)-APPT;g-PPT |
Introduction of 34080-08-5 :
(20S)-Protopanaxatriol is a metabolite of ginsenoside, works through the glucocorticoid receptor (GR) and oestrogen receptor (ER), and is also a LXRα inhibitor. IC50 & Target: Glucocorticoid receptor, Oestrogen receptor[1], LXRα[2] In Vitro: (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and oestrogen receptor (ER) in human umbilical vein endothelial cells (HUVECs). (20S)-Protopanaxatriol (g-PPT) increases [Ca2+]i with an EC50 of 482 nM in HUVECs. (20S)-Protopanaxatriol (1 µM) elevates NO production via ERβ[1]. (20S)-Protopanaxatriol (PPT) inhibits the autonomous transactivation of Gal4-LXRα LBD, the T0901317-dependent transcription of SREBP-1c and its promoter. (20S)-Protopanaxatriol (10 μg/mL) blocks the recruitment of RNA polymerase II to the LXRE region of SREBP-1c. (20S)-Protopanaxatriol also inhibits T0901317-dependent transcription of LXRα target genes related to lipogenesis, and reduces T0901317-induced cellular triglyceride (TG) accumulation in primary hepatocytes, but does not alter transcription of ABCA1, also an LXRα target gene[2].
| Purity |
NLT 98% |
| Storage |
at 20ºC 2 years |
*The above information is for reference only.
